Hemab Therapeutics Statistics
NASDAQ: COAGHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
28.70+0.33 (+1.16%)
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 28.70 0.00%
Hemab Therapeutics by the numbers
Hemab Therapeutics has a market capitalization of $1.34 billion based on 46.71M shares outstanding. With trailing EPS of $-4.33, Hemab Therapeutics is unprofitable on a 12-month basis, so earnings-based valuation ratios do not apply. The stock trades 34.4% below its 50-day average and 23.0% below its 200-day average.
Average daily trading volume is 453.50K shares, or about $13.0 million in dollar volume.
Summary generated from market data by MetaCap's automated system. Methodology
COAG valuation vs. peer median
| Metric | COAG | Peer median | Difference |
|---|---|---|---|
| Market cap | $1.34B | $1.31B | +2% |
| Avg. volume | 453.50K | 680.73K | -33% |
Peer median across 8 companies: INBX, REPL, TSHA, MAZE, IMCR, IMTX, VOR, MGTX.
Valuation
- Market cap
- $1.34B
- EPS (TTM)
- $-4.33
- Shares outstanding
- 46.71M
Price and trading
- Previous close
- 28.37
- Open
- 28.25
- Day range
- 27.38 – 28.98
- 52-week range
- 23.00 – 55.42
- Beta
- —
- Volume
- 377.18K
- Average volume
- 453.50K
Dividends and events
- Annual dividend
- None
- Next earnings date
- Aug 11, 2026
Additional statistics
- Market Cap
- 1.34B
- Forward Pe
- -11.31
- Eps
- -4.33
- Dividend Yield
- 0.00%
- Dividend Rate
- 0.00
- Week52 High
- 55.42
- Week52 Low
- 23.00
- Avg Volume
- 453.50K
- Shares Outstanding
- 46.71M
- Ma50
- 43.72
- Ma200
- 37.26
- Earnings Date
- Aug 11, 2026
- Pct From52w High
- -48.21%
- Pct From52w Low
- 24.78%